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Joseph Scuorzo, DO, George Prousi, MD, Grace Chong, DO, Brian Costello, DO 
Lehigh Valley Health Network, Allentown, Pa.
INTRODUCTION
Autoimmune hemolytic anemia is an acquired disease  
of antibody induced red blood cell (RBC) destruction 
that occurs acutely and can be life-threatening. Warm 
thermal-based reactive autoantibodies are predomi-
nately involved, however, other etiologies including 
drug-induced immune hemolytic anemia (DIIHA) are 
possible. The prevalence of DIIHA is rare affecting  
1 in 1 million, but makes up to 10% of all autoimmune 
 hemolytic anemia cases and attributes to a 3.6% 
 mortality rate in 33 months. There are over 150 known 
medications that cause this pathology, and though 
rare, should be considered during the workup of an 
acute hemolytic crisis. 
CASE PRESENTATION
A 70-year-old female presented with symptoms of 
 nausea, vomiting, abdominal pain and dizziness, as 
well as complaints of dark urine and dark stool. On 
physical exam, she exhibited scleral icterus and diffuse 
jaundice. She was afebrile and tachycardic, with other 
vitals within normal limits. Further evaluation revealed 
the addition of Bactrim and indomethacin as new 
 medications. Timing of symptoms occurred after one 
day of initiating Bactrim and one week after the start of 
indomethacin. Pertinent laboratory data included a 
 Hemoglobin of 5.6, total bilirubin greater than 35, 
 Direct Bilirubin 25, LDH greater then 1000, and a low 
haptoglobin (<7). CT Abdomen/Pelvis revealed mild 
splenomegaly and no infection or occult malignancies 
were suspected. Direct Anti-globin test (DAT) was pos-
itive for IgG, CD3; indicative of warm or drug-induced 
hemolytic anemia. She was stabilized promptly with 
blood transfusions followed by high dose steroids.
DISCUSSION
Our patient presented with a clinical picture consistent 
with intravascular hemolytic anemia likely secondary  
to trimethoprim-sulfamethoxazole and concern for 
 Glucose-6-Phosphate-Dehydrogenase (G6PD) 
deficiency. Diagnostic efforts revealed the patient to  
be DAT positive, supporting the diagnosis of a drug- 
induced process or primary warm type hemolytic 
anemia. Mainstays of therapy predominately consists 
of prednisolone and transfusions with IVIG and 
plasmapheresis for severe or refractory cases. 
Supportive treatment with drug discontinuation, folic 
acid, anticoagulation, and medications to suppress the 
side effects of steroid therapy are also recommended. 
Given the severity of presentation with correlating 
mortality of drug-induced hemolytic anemias, decisions 
to prescribe potentially unnecessary medications 
should include thought of more than just the common 
adverse effects. 
